Abstract
The skin is the ultimate example of the function of innate immunity, it alerts the host of danger by many systems including sensing pathogen-associated molecule patterns (PAMPs) through Toll-like receptors and other pattern recognition receptors (PRRs), yet normally provides defense without inflammation. The skin responds rapidly to invading microbes by producing antimicrobial peptides or other antimicrobial intermediates before cytokine release results in inflammation. To achieve maximal immune responses for clearing invading microbes, the activation of select PRRs in skin then initiates and shapes adaptive immune responses through the activation of dendritic cells and recruitment of T cell subsets. Importantly, cross-talk between TLRs can influence this system in several ways including augmenting or suppressing the immune response. As a consequence of their pivotal role, TLR responses need to be tightly controlled by associated negative regulators or negative feedback loops to prevent detrimental effects from TLRs overactivation. This review focuses on describing the involvement of TLRs in the development of skin infections and inflammatory diseases, and highlights the potential application of TLR agonists or antagonists in these skin diseases.
Keywords: Toll-like receptors, TLR signaling, inflammatory cytokines, antimicrobial peptides, cross talk, negative regulators, skin infections, inflammatory diseases
Infectious Disorders - Drug Targets
Title: Toll-Like Receptors in Skin Infections and Inflammatory Diseases
Volume: 8 Issue: 3
Author(s): Yuping Lai and Richard L. Gallo
Affiliation:
Keywords: Toll-like receptors, TLR signaling, inflammatory cytokines, antimicrobial peptides, cross talk, negative regulators, skin infections, inflammatory diseases
Abstract: The skin is the ultimate example of the function of innate immunity, it alerts the host of danger by many systems including sensing pathogen-associated molecule patterns (PAMPs) through Toll-like receptors and other pattern recognition receptors (PRRs), yet normally provides defense without inflammation. The skin responds rapidly to invading microbes by producing antimicrobial peptides or other antimicrobial intermediates before cytokine release results in inflammation. To achieve maximal immune responses for clearing invading microbes, the activation of select PRRs in skin then initiates and shapes adaptive immune responses through the activation of dendritic cells and recruitment of T cell subsets. Importantly, cross-talk between TLRs can influence this system in several ways including augmenting or suppressing the immune response. As a consequence of their pivotal role, TLR responses need to be tightly controlled by associated negative regulators or negative feedback loops to prevent detrimental effects from TLRs overactivation. This review focuses on describing the involvement of TLRs in the development of skin infections and inflammatory diseases, and highlights the potential application of TLR agonists or antagonists in these skin diseases.
Export Options
About this article
Cite this article as:
Lai Yuping and Gallo L. Richard, Toll-Like Receptors in Skin Infections and Inflammatory Diseases, Infectious Disorders - Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/1871526510808030144
DOI https://dx.doi.org/10.2174/1871526510808030144 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Roles of Biosurfactants in Biofilms
Current Pharmaceutical Design Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Can Infectious Biofilm be Controlled by Blocking Bacterial Communication?
Medicinal Chemistry The Family of Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Strategies for Antimicrobial Drug Delivery to Biofilm
Current Pharmaceutical Design Oral Colonization by Nosocomial Pathogens During Hospitalization in Intensive Care Unit and Prevention Strategies
Recent Patents on Anti-Infective Drug Discovery Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology Antibiotics in Endophthalmitis: Microbiological and Pharmacokinetic Considerations
Current Clinical Pharmacology Antibiotic Dosage Regimens in Respiratory Tract Infections in the Pharmacokinetic/Pharmacodynamic Era
Current Respiratory Medicine Reviews New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry Perceval Sutureless Valve – are Sutureless Valves Here?
Current Cardiology Reviews Development and Validation of a UV-Spectrophotometric Method for Determination of Flucloxacillin Sodium in Capsules
Current Pharmaceutical Analysis Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Short Term Statin Treatment Improves Survival and Differentially Regulates Macrophage-Mediated Responses to Staphylococcus aureus
Current Pharmaceutical Biotechnology Optimal antibiotic dosage for chronic kidney disease patient: a pharmacological manual for oral clinicians
Recent Patents on Anti-Infective Drug Discovery Evaluation of <sup>99m</sup>Technetium-Vancomycin Imaging Potential in Experimental Rat Model for the Diagnosis of Infective Endocarditis
Current Medical Imaging Use of Nanoparticles as Therapy for Methicillin-Resistant Staphylococcus aureus Infections
Current Drug Metabolism Unique Applications of Novel Antifungal Drug Combinations
Anti-Infective Agents in Medicinal Chemistry Antibiotic Susceptibility and Treatment of Brucellosis
Recent Patents on Anti-Infective Drug Discovery New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)
Current Pharmaceutical Design